How should we taper duloxetine, quetiapine, and lamotrigine in a patient with acute on chronic kidney disease and an estimated glomerular filtration rate less than 10 mL/min/1.73 m²?

Medication Management in Severe Kidney Disease (eGFR <10)

In a patient with acute-on-chronic kidney disease and eGFR <10 mL/min/1.73m², duloxetine must be discontinued immediately due to contraindication in severe renal impairment, while quetiapine and lamotrigine can be continued with dose adjustments and careful monitoring.

Duloxetine - DISCONTINUE

Duloxetine is contraindicated and should be stopped in this patient. The FDA label explicitly states to "avoid use in patients with severe renal impairment, GFR <30 mL/minute" 1. With eGFR <10, this patient has end-stage renal disease where duloxetine exposure increases approximately 2-fold and metabolite exposure increases 7-9 fold 1, 2. The current dose of 180 mg daily is already 1.5-3 times the maximum recommended dose (60-120 mg), making this situation particularly dangerous.

Duloxetine Tapering Protocol:

Given the high dose (180 mg daily) and severe renal impairment:

• Week 1-2: Reduce to 120 mg daily
• Week 3-4: Reduce to 60 mg daily
• Week 5-6: Reduce to 30 mg daily
• Week 7: Discontinue completely

The FDA label warns that abrupt discontinuation causes dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue 1. A gradual taper over 6-7 weeks minimizes these withdrawal symptoms while expediting removal of a contraindicated medication.

Critical monitoring during taper: Watch for serotonin discontinuation syndrome, worsening depression/anxiety, and uremic symptoms that may have been masked by duloxetine.

Quetiapine - CONTINUE WITH MONITORING

Quetiapine 300 mg daily can be continued. Quetiapine is primarily hepatically metabolized with minimal renal excretion, so dose adjustment based solely on renal function is not required. However, in the context of acute-on-chronic kidney disease with uremia, start at the lower end of dosing if initiating, but the current 300 mg can be maintained with close monitoring for:

• Excessive sedation (uremia increases CNS sensitivity)
• Orthostatic hypotension (volume status changes in acute kidney injury)
• QTc prolongation (electrolyte abnormalities common in severe CKD)

No taper needed unless adverse effects emerge.

Lamotrigine - REDUCE DOSE SIGNIFICANTLY

Lamotrigine requires substantial dose reduction but can be continued. While lamotrigine itself has minimal pharmacokinetic changes in renal failure, its elimination half-life approximately doubles from 25 hours to 50 hours in uremic patients 3. The current dose of 100 mg twice daily (200 mg total) is excessive for eGFR <10.

Lamotrigine Dose Adjustment:

Research specifically recommends 100 mg every 48 hours (every other day) when creatinine clearance is below 10 mL/min 3.

Tapering schedule from 100 mg BD:

• Week 1-2: 100 mg daily (reduce from BD to once daily)
• Week 3 onwards: 100 mg every other day (alternate day dosing)

This achieves a 75% dose reduction appropriate for the degree of renal impairment. Lamotrigine has a wide therapeutic window, making this adjustment relatively safe. The gradual reduction over 2-3 weeks prevents precipitating seizures or mood destabilization if used for bipolar disorder.

Important consideration: If the patient requires hemodialysis, lamotrigine is significantly removed during dialysis (17% per session, with half-life dropping from 60 hours to 12 hours during dialysis) 3. A supplemental dose of 50 mg post-dialysis may be needed.

Critical Clinical Pitfalls

1. Do not delay duloxetine discontinuation - The combination of severe renal impairment and supratherapeutic dosing creates high risk for serotonin syndrome, hyponatremia (especially dangerous with CKD), and urinary retention 1.

2. Monitor for drug accumulation - With acute-on-chronic kidney disease, the "acute" component may improve, potentially requiring dose re-adjustment if renal function recovers.

3. Assess for uremic symptoms - Duloxetine may have been masking uremic neuropathy symptoms that will emerge during taper. This is actually beneficial as it provides clearer indication for renal replacement therapy.

4. Electrolyte monitoring - Check sodium weekly during duloxetine taper (SIADH risk), and potassium/calcium regularly for all medications given the severe CKD 1.

5. Psychiatric stability - Coordinate with psychiatry given the high doses suggest difficult-to-treat psychiatric illness. Alternative agents safe in ESRD (such as sertraline at reduced doses) should be considered as duloxetine is tapered.